Gln 27 →Gluβ 2 ‐Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

• Published in: Basic & clinical pharmacology & toxicology Vol. 104; no. 5; pp. 374 - 378
• Main Authors: Troncoso, Rodrigo, Moraga, Francisco, Chiong, Mario, Roldán, Juan, Bravo, Roberto, Valenzuela, Rodrigo, Díaz‐Araya, Guillermo, Del Campo, Andrea, Sanhueza, Carlos, Rodriguez, Andrea, Vukasovic, José Luis, Mellado, Rosemarie, Greig, Douglas, Castro, Pablo F., Lavandero, Sergio
• Format: Journal Article
• Language: English
• Published: 01.05.2009
• ISSN: 1742-7835; 1742-7843
• DOI: 10.1111/j.1742-7843.2008.00370.x

We investigated the clinical response of chronic heart failure patients with β 2 ‐adrenergic receptor Gln 27 →Glu polymorphism treated for 6 months with carvedilol, a α/β‐antagonist with antioxidant properties. The 6‐min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln 27 →Gluβ 2 ‐adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27 β 2 ‐adrenergic receptor allele. There were however, no significant changes in patients with the Gln 27 β 2 ‐adrenergic receptor variant.